Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Sara M. Tolaney MD, MPH Advisory Board

Lee S. Schwartzberg MD, FACP Advisory Board

Guru P. Sonpavde MD Advisory Board

See All Experts

featured

Published in Oncology and

Expert Opinion / Interview · November 01, 2018

ESMO 2018: Overall Survival With Palbociclib Plus Fulvestrant

Interview by

Bradley A McGregor MD

Interview with

Timothy J Pluard MD

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Additional Info

Disclosures

Disclosure statements are available on the authors' profiles:

Bradley McGregor MD

Timothy Pluard MD

story of the week

Stereotactic Body Radiotherapy for Localized Prostate Cancer

N. Engl. J. Med · November 16, 2024

updated
featured

Efficacy of Durvalumab After Chemoradiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

N. Engl. J. Med · November 15, 2024

updated
featured

Zanubrutinib, Obinutuzumab, and Venetoclax as a First-Line Treatment for TP53-Mutant Mantle Cell Lymphoma

Blood · November 13, 2024
story of the week

Nivolumab Plus AVD for Advanced-Stage Classic Hodgkin's Lymphoma

N. Engl. J. Med · November 13, 2024
featured

Efficacy and Safety of Elacestrant in ER+/HER2− MBC With ESR1-Mutated Tumors Based on Prior Duration of Endocrine Therapy Plus CDK4/6i and in Clinical Subgroups

Clin. Cancer Res · November 12, 2024
story of the week

Ponsegromab for Treating Cancer Cachexia

N. Engl. J. Med · November 12, 2024

updated
featured

Clinical Validation of a Tissue-Agnostic Genome-Wide Methylome Enrichment Molecular Residual Disease Assay for Head and Neck Malignancies

Ann. Oncol · November 07, 2024
featured

Belantamab Mafodotin, Pomalidomide, and Dexamethasone for Triple Class–Exposed/Refractory Relapsed Multiple Myeloma

Blood Cancer J · November 07, 2024
featured

First-in-Human Study of MTA-Cooperative PRMT5 Inhibitor AMG 193 in Patients With MTAP-Deleted Solid Tumors

Ann. Oncol · November 06, 2024
story of the week

Perioperative Durvalumab With Neoadjuvant Chemotherapy for Operable Bladder Cancer

N. Engl. J. Med · November 05, 2024

updated
featured

Relationship Between Soluble IL-2 Receptor Levels and Prognosis in DLBCL

Ann Hematol · November 05, 2024

Metastatic Breast Cancer

ESMO 2018: Overall Survival With Palbociclib Plus Fulvestrant

Additional Info

Further Reading

Stereotactic Body Radiotherapy for Localized Prostate Cancer

Efficacy of Durvalumab After Chemoradiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Zanubrutinib, Obinutuzumab, and Venetoclax as a First-Line Treatment for TP53-Mutant Mantle Cell Lymphoma

Nivolumab Plus AVD for Advanced-Stage Classic Hodgkin's Lymphoma

Efficacy and Safety of Elacestrant in ER+/HER2− MBC With ESR1-Mutated Tumors Based on Prior Duration of Endocrine Therapy Plus CDK4/6i and in Clinical Subgroups

Ponsegromab for Treating Cancer Cachexia

Clinical Validation of a Tissue-Agnostic Genome-Wide Methylome Enrichment Molecular Residual Disease Assay for Head and Neck Malignancies

Belantamab Mafodotin, Pomalidomide, and Dexamethasone for Triple Class–Exposed/Refractory Relapsed Multiple Myeloma

First-in-Human Study of MTA-Cooperative PRMT5 Inhibitor AMG 193 in Patients With MTAP-Deleted Solid Tumors

Perioperative Durvalumab With Neoadjuvant Chemotherapy for Operable Bladder Cancer

Relationship Between Soluble IL-2 Receptor Levels and Prognosis in DLBCL

Related Videos